Jefferies has recently initiated Amicus Therapeutics, Inc. (FOLD) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on May 30, 2024, Wells Fargo had initiated the stock to Overweight, setting a price target of $18. Guggenheim also raised Buy rating with a price target of $13. Additionally, Morgan Stanley raised rating on December 19, 2023, with a target price of $20. Morgan Stanley analysts, in their report published on September 9, 2022, also initiated research coverage and set a price target of $14 for Amicus Therapeutics, Inc.’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Amicus Therapeutics, Inc. (FOLD) Stock Trading Recap
On Monday, Amicus Therapeutics, Inc. (FOLD) stock saw a modest uptick, ending the day at $12.01 which represents a slight increase of $0.11 or 0.92% from the prior close of $11.9. The stock opened at $11.85 and touched a low of $11.79 during the day, reaching a high of $12.18. The volume of shares traded was 2.36 million falling short of the average volume of 2.67 million.
Sponsored
FOLD Stock Performance and Moving Averages
In recent trading, Amicus Therapeutics, Inc. (FOLD) stock price has shown some volatility, fluctuating 15.26% over the last five trades and 6.38% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 11.00%, and it has gained 16.49% in the previous three months. Currently, FOLD is trading at 11.88%, 7.47%, and 7.08% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, FOLD, a Healthcare sector stock, is trading -17.57% below its 52-week high but remains 33.15% above its 52-week low. The Average True Range (ATR) (14 days) of 0.42 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Amicus Therapeutics, Inc.’s Profitability and Valuation Ratios
Amicus Therapeutics, Inc.’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -5.58% and a profit margin of -26.23%, with a gross margin of 11.00%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Amicus Therapeutics, Inc.’s market capitalization stands at $3.56 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 61.47. Additionally, the Price-to-Sales Ratio is 7.82, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 26.86, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 2.55% of Amicus Therapeutics, Inc. (FOLD)’s shares, while financial institutions hold 105.23%.
Notable insider trades include MCGLYNN MARGARET G, Director at Amicus Therapeutics, Inc. (FOLD), who sold 7500 shares on Mar 05 ’24, at $13.4 each, totaling $0.10 million. On Mar 01 ’24, Campbell Bradley L, President and CEO, sold 15833 shares for $13.14 each, amounting to $0.21 million. Additionally, on Mar 01 ’24, Crowley John F sold 29181 shares at $13.35 each, generating $0.39 million.
